Abstract
Historically, patients with resectable stage III and IV tumors were treated with combined surgery and radiation. Early attempts at improving results by incorporating chemotherapy in the postoperative setting have been largely unsuccessful or inconsistent. However, longer follow-up of recent landmark trials exploring concurrent chemotherapy and radiotherapy have clarified the issue, supporting concurrent cisplatin based chemotherapy for high risk patients. The survival benefit seen in the concurrent chemoradiotherapy trials appears to stem from improved locoregional control, as no reduction in systemic failure has been observed. Another evolving approach to post-operative head and neck radiotherapy is the use of altered fractionation schedules. There are several recent studies exploring either hyperfractionated or accelerated radiotherapy, as a response to the issue of accelerated tumor repopulation, providing evidence that such treatment is beneficial in selected patients. There are several questions worthy of further clinical research, and these will likely continue to follow the lead of nonsurgically managed head and neck cancer. Preliminary data suggests that IMRT can be tailored to postoperative patients, and target volumes defined such that morbidity can be minimized without jeopardizing tumor control. Biological modifiers of radiotherapy may allow selective radiosensitization without the morbidity of concurrent chemotherapy.
Keywords: head and neck cancer, radiotherapy, postoperative, chemotherapy, imrt, hyperfractionation
Current Cancer Therapy Reviews
Title: New Approaches to Postoperative Radiotherapy for Cancer of the Head and Neck
Volume: 1 Issue: 1
Author(s): Perri Prellop and Roger Ove
Affiliation:
Keywords: head and neck cancer, radiotherapy, postoperative, chemotherapy, imrt, hyperfractionation
Abstract: Historically, patients with resectable stage III and IV tumors were treated with combined surgery and radiation. Early attempts at improving results by incorporating chemotherapy in the postoperative setting have been largely unsuccessful or inconsistent. However, longer follow-up of recent landmark trials exploring concurrent chemotherapy and radiotherapy have clarified the issue, supporting concurrent cisplatin based chemotherapy for high risk patients. The survival benefit seen in the concurrent chemoradiotherapy trials appears to stem from improved locoregional control, as no reduction in systemic failure has been observed. Another evolving approach to post-operative head and neck radiotherapy is the use of altered fractionation schedules. There are several recent studies exploring either hyperfractionated or accelerated radiotherapy, as a response to the issue of accelerated tumor repopulation, providing evidence that such treatment is beneficial in selected patients. There are several questions worthy of further clinical research, and these will likely continue to follow the lead of nonsurgically managed head and neck cancer. Preliminary data suggests that IMRT can be tailored to postoperative patients, and target volumes defined such that morbidity can be minimized without jeopardizing tumor control. Biological modifiers of radiotherapy may allow selective radiosensitization without the morbidity of concurrent chemotherapy.
Export Options
About this article
Cite this article as:
Prellop Perri and Ove Roger, New Approaches to Postoperative Radiotherapy for Cancer of the Head and Neck, Current Cancer Therapy Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573394052952537
DOI https://dx.doi.org/10.2174/1573394052952537 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments
Current Medicinal Chemistry Current Advances in the Development of Anticancer Drugs Targeting Tyrosine Kinases of the Src Family
Current Drug Therapy Bioinformatics Analysis of Functional Relations Between CNPs Regions
Current Bioinformatics STAT3 as a Central Regulator of Tumor Metastases
Current Molecular Medicine Advanced Protein Drugs and Formulations
Current Protein & Peptide Science Lessons we Learned from High-Throughput and Top-Down Systems Biology Analyses about Glioma Stem Cells
Current Pharmaceutical Design miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets Comparative DFT Study of 5-Fluorouracil Adsorption on Silica and Graphene for Bio-Medical Applications
Micro and Nanosystems Cancer Stem Cells with Overexpression of Neuronal Markers Enhance Chemoresistance and Invasion in Retinoblastoma
Current Cancer Drug Targets Antitumor Activity of Zinc Nanoparticles Synthesized with Berberine on Human Epithelial Colorectal Adenocarcinoma (Caco-2) Cells through Acting on Cox-2/NF-kB and p53 Pathways
Anti-Cancer Agents in Medicinal Chemistry Mechanisms of Cytotoxicity of Anticancer Titanocenes
Anti-Cancer Agents in Medicinal Chemistry ‘Ribozoomin’ – Translation Initiation from the Perspective of the Ribosome-bound Eukaryotic Initiation Factors (eIFs)
Current Protein & Peptide Science Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway
Current Cancer Therapy Reviews Pharmacogenomics of Breast Cancer Targeted Therapy: Focus on Recent Patents
Recent Patents on DNA & Gene Sequences Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Inhibition of TGF- Signaling for the Treatment of Tumor Metastasis and Fibrotic Diseases
Current Signal Transduction Therapy Editorial [Immunogenicity of Biotherapeutics: A Need for Consensus on Flexibility of Approach (Guest Editor: Stewart Barker)]
Current Drug Safety Withanolides: Biologically Active Constituents in the Treatment of Alzheimer’s Disease
Medicinal Chemistry Use of Cell Lines in the Investigation of Pharmacogenetic Loci
Current Pharmaceutical Design Targeting Glioblastoma Stem Cells: Cell Surface Markers
Current Medicinal Chemistry